ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
ENDRA Life Sciences Inc. (NDRA) filed this Current Report on Form 8-K on May 12, 2022. The filing serves to announce the company's financial results for the quarter ended March 31, 2022. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a notification that results were announced via a press release (Exhibit 99.1) but does not include the financial data itself.
Material Changes
No material changes or comparative financial data are detailed within the text of this Form 8-K. The filing references a press release for the actual results but does not summarize the changes versus the prior period.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act. Consequently, it is not subject to the liabilities of that section nor incorporated by reference in other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 12, 2022) for actual Q1 2022 financial figures.
- Verify the company's status as an emerging growth company.
- Confirm the trading symbols NDRA (Common Stock) and NDRAW (Warrants) on Nasdaq.
- Check subsequent filings for the full audited or reviewed financial statements referenced in the press release.